DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 022110
NDA 022110 describes VIBATIV, which is a drug marketed by Theravance Biopharma and is included in one NDA. It is available from two suppliers. There are eleven patents protecting this drug. Additional details are available on the VIBATIV profile page.
The generic ingredient in VIBATIV is telavancin hydrochloride. Two suppliers are listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
The generic ingredient in VIBATIV is telavancin hydrochloride. Two suppliers are listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
Summary for 022110
| Tradename: | VIBATIV |
| Applicant: | Theravance Biopharma |
| Ingredient: | telavancin hydrochloride |
| Patents: | 11 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 022110
| Ingredient-type | Lipoglycopeptides |
Suppliers and Packaging for NDA: 022110
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VIBATIV | telavancin hydrochloride | POWDER;IV (INFUSION) | 022110 | NDA | Theravance, Inc. | 52118-001 | N | 52118-001-01 |
| VIBATIV | telavancin hydrochloride | POWDER;IV (INFUSION) | 022110 | NDA | Theravance, Inc. | 52118-002 | N | 52118-002-01 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;IV (INFUSION) | Strength | EQ 250MG BASE/VIAL | ||||
| Approval Date: | Sep 11, 2009 | TE: | RLD: | Yes | |||||
| Patent: | ➤ Sign Up | Patent Expiration: | Sep 11, 2023 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | METHOD FOR TREATING BACTERIAL INFECTION | ||||||||
| Patent: | ➤ Sign Up | Patent Expiration: | Aug 24, 2022 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ➤ Sign Up | Patent Expiration: | Jun 5, 2021 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
